Breaking News

PAREXEL Appoints SVP and CFO

June 14, 2013

Bank brings global experience

Ingo Bank has been appointed senior vice president at PAREXEL and will become chief financial officer on September 1. He joins the company from Royal Philips, where he served as chief financial officer and executive vice president of Philips Healthcare. Mr. Bank will be based at the company's corporate headquarters in Waltham, MA. He succeeds outgoing James F. Winschel, Jr., who will serve as executive vice president until he retires in 2014.
 
"PAREXEL is pleased to welcome a leader with Ingo's global experience.  He has an impressive record overseeing financial management across a variety of industry sectors. Ingo's business acumen and focus on continuous improvement and performance will serve us well as we drive our growth strategy and focus on continuing to deliver profitable results to our stakeholders," said Josef von Rickenbach, chairman and chief executive officer, PAREXEL.
 
"As we welcome Ingo Bank to PAREXEL, I would also like to recognize Jim Winschel's commitment to overseeing the worldwide financial management for the Company. Under his leadership, PAREXEL's market capitalization grew from $225 million to $2.7 billion, service revenue increased from $378 million to $1.7 billion and backlog grew from $385 million to over $4 billion," said Mr. von Rickenbach. "We thank Jim for his efforts and his continued involvement in the company."

blog comments powered by Disqus
  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • A Biologic Innovator

    A Biologic Innovator's Pursuit to Uphold Patents

    Kristin Brooks, Contract Pharma||October 12, 2015
    Amgen v. Sandoz biosimilars litigation could impact the industry for years to come

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies